TB-500

TB-500 is a synthetic 17-amino-acid peptide fragment (Ac-LKKTETQ, residues 17-23) of full-length Thymosin Beta-4 (Tβ4), a 43-amino-acid actin-binding protein found across most mammalian tissues. The fragment retains the core WH2 actin-binding domain but lacks the nuclear localisation signal (residues 26-31) and the receptor-interaction C-terminus of the parent protein. In the research peptide market TB-500 and Thymosin Beta-4 are often used interchangeably, but they are not molecularly identical — a distinction that matters when reading the literature, because most high-quality human trial data describes full-length Tβ4, not the TB-500 fragment.

Mechanistically, TB-500 binds monomeric G-actin in a 1:1 ratio with a dissociation constant of 0.5-0.7 μM, sequestering 40-50% of the cytosolic G-actin pool and preventing premature polymerisation into F-actin. This creates a rapid-release reservoir of G-actin that the cell can draw from during migration, lamellipodia formation and wound repair. Unlike gelsolin or cofilin, TB-500 does not sever F-actin or cap filament ends; it acts purely as a sequestering agent at the barbed-end groove. Beyond actin dynamics, it activates integrin-linked kinase (ILK), which phosphorylates Akt at Ser473 and GSK-3β at Ser9, promoting cell survival, migration and NF-κB-mediated resolution of inflammation. Preclinical work also documents angiogenic effects via enhanced endothelial migration and upregulated integrins. Full-length Tβ4 has additional nuclear signalling that TB-500 does not replicate, but in the primary actin-sequestration and ILK pathways the fragment appears comparable in animal models.

Human clinical evidence is limited but more advanced than most research peptides. RegenTree's RGN-259, an ophthalmic formulation of thymosin beta-4, reached Phase 2/3 trials — NCT01387347 reported a 37% improvement in corneal staining versus 18% on placebo in dry eye disease (p<0.01), while the neurotrophic keratitis Phase 3 (NCT04145744) did not meet its primary endpoint. A small Phase 2 cardiac study (NCT01311521) of intravenous Tβ4 at 300-1500 μg/kg after myocardial infarction improved ejection fraction by roughly 6% at six months versus 2% on placebo, though the difference was not statistically significant. In total there are approximately 5-7 human studies of thymosin beta-4 and its derivatives, concentrated in ocular and cardiac indications. There are no direct TB-500 fragment trials in humans; efficacy claims for the fragment are extrapolated from Tβ4 on the basis of shared actin-binding biology. Preclinical evidence in animals is considerably stronger: roughly 40% faster skin wound closure in rodent models, reduced cardiac fibrosis and improved progenitor-cell activation after infarction, and 25-30% improvements in functional recovery in rat spinal cord injury.

Reported dosing again divides clean research from off-label use. Rodent skin-wound protocols use 10-60 mg/kg subcutaneously or intramuscularly daily. Cardiac-repair mouse models have employed 100-300 μg/kg IV daily after infarction. Off-label human wellness protocols — extrapolated from these models, not from human trial data — typically run 2-10 mg per week total, divided into 2-3 doses. A common loading schedule is 4-8 mg per week for 4-6 weeks followed by a maintenance phase of 2-5 mg per week; the 48-72 hour half-life supports weekly cadence. Subcutaneous is the preferred route for systemic effects, with intramuscular reserved for localised muscle or joint injury. Cycles of 6-12 weeks on and 4 weeks off are reported in user literature, though this pattern is a convention rather than a trial-derived recommendation.

The safety conversation around TB-500 has two distinct registers. Short-term: Phase 2 ocular trials with over 500 participants found no severe adverse events; mild injection-site reactions, transient fatigue and headaches are reported at the higher end of off-label dosing (>10 mg/week). Animal toxicity studies have shown no organ damage or genotoxicity up to 60 mg/kg. Long-term: the theoretical concern is angiogenesis. Because TB-500 drives endothelial migration and ILK-Akt signalling, it is plausibly contraindicated in any patient with an active or suspected malignancy — a concern that remains theoretical but is mechanistically credible. Human long-term safety data simply does not exist.

Regulatory status is straightforward. The World Anti-Doping Agency has prohibited TB-500 and Tβ4 since 2010 under the S2 anabolic agents category, and detection methods can identify the peptide in urine weeks after administration — a relevant point for competitive athletes. The FDA has not approved TB-500 for any indication, and it sits on the same research-peptide grey shelf as BPC-157, with similar compounding restrictions and interstate-commerce warning letter history. In veterinary medicine the peptide is used off-label in equine practice for tendon repair at 10-20 mg subcutaneously weekly, and it is prohibited under USEF and FEI competition rules.

For a reader weighing TB-500 specifically, the most useful filter is to separate the fragment (TB-500 sold on peptide markets) from the parent molecule (Tβ4, which has real Phase 2/3 data). Most efficacy claims made for TB-500 in marketing copy are citing Tβ4 research that applies to the fragment only by analogy. That does not make the peptide useless — the actin-binding mechanism is shared — but it does mean the evidence bar for the fragment specifically is lower than it often appears.